FY2024 Earnings Estimate for Masimo Issued By Zacks Research

Masimo Co. (NASDAQ:MASI) – Zacks Research issued their FY2024 earnings per share estimates for shares of Masimo in a report issued on Wednesday, February 19th. Zacks Research analyst I. Bandyopadhyay anticipates that the medical equipment provider will post earnings per share of $4.10 for the year. The consensus estimate for Masimo’s current full-year earnings is $4.10 per share. Zacks Research also issued estimates for Masimo’s Q4 2024 earnings at $1.49 EPS.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%.

Other research analysts also recently issued reports about the company. Piper Sandler boosted their target price on Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 18th. Stifel Nicolaus restated a “buy” rating and set a $190.00 target price (up from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Raymond James boosted their target price on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research note on Friday, December 27th. Needham & Company LLC restated a “hold” rating on shares of Masimo in a research note on Wednesday, January 22nd. Finally, Wells Fargo & Company boosted their price target on Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Masimo presently has a consensus rating of “Moderate Buy” and an average price target of $191.40.

Masimo Stock Down 0.7 %

Shares of MASI stock opened at $169.54 on Monday. Masimo has a 1-year low of $101.61 and a 1-year high of $184.51. The stock’s fifty day moving average price is $172.65 and its 200 day moving average price is $152.54. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The company has a market cap of $9.08 billion, a price-to-earnings ratio of 116.92 and a beta of 1.02.

Hedge Funds Weigh In On Masimo

A number of large investors have recently bought and sold shares of MASI. Allspring Global Investments Holdings LLC raised its holdings in Masimo by 5,340.9% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,394 shares of the medical equipment provider’s stock worth $319,000 after purchasing an additional 2,350 shares during the period. State of Alaska Department of Revenue grew its position in shares of Masimo by 7.2% in the third quarter. State of Alaska Department of Revenue now owns 5,139 shares of the medical equipment provider’s stock valued at $685,000 after purchasing an additional 345 shares in the last quarter. SteelPeak Wealth LLC purchased a new stake in shares of Masimo in the third quarter valued at approximately $570,000. Roubaix Capital LLC grew its position in shares of Masimo by 37.0% in the third quarter. Roubaix Capital LLC now owns 34,041 shares of the medical equipment provider’s stock valued at $4,539,000 after purchasing an additional 9,202 shares in the last quarter. Finally, Malaga Cove Capital LLC purchased a new position in Masimo in the third quarter worth approximately $401,000. Institutional investors and hedge funds own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.